CNBC's Jim Cramer said Wednesday that Mylan's lifesaving EpiPen device shouldn't be only obtainable for the rich.
The pharmaceutical company has been scrutinized by consumers and public officials after reports showed it raised prices for its auto-injection device, which counteracts severe allergic reaction known as anaphylaxis.
"This is something I think there should be some compassionate use for in payout," Cramer said on "Squawk on the Street." "They should have a subsidy for this thing because it's seconds ... and you have to know how to use it .. and it should not just have to be for rich people."
On Monday, Mylan released a statement saying the company has worked over the past few years to increase "anaphylaxis awareness, preparedness and access to treatment" for those living with the life-threatening allergies.
NBC News reported Monday that a U.S. senator asked the Federal Trade Commission to investigate Mylan's trade practices.